Familial pancreatic Cancer in Italy. Risk assessment, screening programs and clinical approach: A position paper from the Italian Registry
Familial pancreatic Cancer in Italy. Risk assessment, screening programs and clinical approach: A position paper from the Italian Registry
复制标题
DOI：
10.1016/j.dld.2010.04.016
复制
发表时间：
2010-09-01
影响因子：
4.5
通讯作者：
Falconi, Massimo
中科院分区：
文献类型：
--
作者：
Del Chiaro, Marco;Zerbi, Alessandro;Falconi, Massimo
在意大利，胰腺癌是肿瘤相关死亡的第五大原因，每年约有7000例新发病例，死亡率为95%。在最近对意大利人群进行的一项前瞻性流行病学研究中，发现约10%的胰腺导管腺癌（PDAC）患者有家族史。意大利家族性胰腺癌登记处的一份立场文件是为了管理这些高危人群。尽管在大多数高危个体中，无法进行基因检测来确定家族易感性，但对于PDAC发生风险高10倍以上的受试者，筛查方案似乎是合理的。然而，这种筛查应该包括在临床试验中，在胰腺疾病方面具有高度专业知识的中心进行，使用最不具侵略性的诊断方式。(C)2010年编辑意大利胃肠病学S.r.l.由爱思唯尔有限公司出版。保留所有权利。
In Italy, pancreatic cancer is the fifth leading cause of tumor related death with about 7000 new cases per year and a mortality rate of 95%. In a recent prospective epidemiological study on the Italian population, a family history was found in about 10% of patients suffering from a ductal adenocarcinoma of the pancreas (PDAC). A position paper from the Italian Registry for Familial Pancreatic Cancer was made to manage these high-risk individuals. Even though in the majority of high-risk individuals a genetic test to identify familial predisposition is not available, a screening protocol seems to be reasonable for subjects who have a >10-fold greater risk for the development of PDAC. However this kind of screening should be included in clinical trials, performed in centers with high expertise in pancreatic disease, using the least aggressive diagnostic modalities. (C) 2010 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.